DYSLIPIDEAMIA Clinical Trials

7 clinical trials for DYSLIPIDEAMIA across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE-3, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH DYSLIPIDEMIA WHO ARE INTOLERANT TO STATINS — RECRUITING
• A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR DYSLIPDEMIA AT RISK OF CARDIOVASCULAR EVENTS — RECRUITING · PHASE3
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF EVOLOCUMAB (AMG 145) IN COMBINATION WITH STATIN THERAPY IN DIABETIC SUBJECTS WITH HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA — RECRUITING
• A PHASE 2 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ARO-APOC3 IN ADULTS WITH DYSLIPIDEMIA — COMPLETED · PHASE2
• A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARO-ANG3 IN ADULTS WITH MIXED DYSLIPIDEMIA — COMPLETED · PHASE2
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VUPANORSEN (PF-07285557) IN STATIN-TREATED PARTICIPANTS WITH DYSLIPIDEMIA — COMPLETED · PHASE2
• EFFECTS OF SELECTIVE INHIBITION OF CHOLESTEROL ABSORPTION WITH EZETIMIBE ON INTESTINAL CHOLESTEROL HOMEOSTASIS IN DYSLIPIDEMIC MEN WITH INSULIN-RESISTANCE - A PILOT STUDY — NOT_YET_RECRUITING

Refine this search